Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 126

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 1
Chunk 126
---
 274,488 253,629 224,550 Diluted 288,366 253,629 224,550 

See accompanying notes to the consolidated financial statements.

Fiscal 2024 Form 10-K86

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 Common Stock Additional Paid-inCapitalAccumulatedOtherComprehensive Income (Loss)Accumulated DeficitTotalStockholders'Equity(in thousands)SharesAmountBalance at December 31, 2021220,978$221 $2,009,945 $(1,087)$(1,218,092)$790,987 Net loss—— — — (314,248)(314,248)Other comprehensive loss—— — (3,678)— (3,678)Issuance of common stock in conjunction with equity plans5,5276 11,224 — — 11,230 Share-based compensation expense—— 78,613 — — 78,613 Balance at December 31, 2022226,505$227 $2,099,782 $(4,765)$(1,532,340)$562,904 Net loss—— — — (306,735)(306,735)Other comprehensive income—— — 4,984 — 4,984 Issuance of common stock following milestone achievement8,9889 84,752 — — 84,761 Issuance of common stock in acquisition of Apton6,1216 76,636 — — 76,642 Issuance of common stock in connection with Apton liquidity event bonus plan169— 2,111 — — 2,111 Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs20,12520 189,180 — — 189,200 Issuance of common stock in conjunction with equity plans5,8366 15,313 — — 15,319 Share-based compensation expense—— 72,118 — — 72,118 Balance at December 31, 2023267,744$268 $2,539,892 $219 $(1,839,075)$701,304 Net loss—— — — (